# Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

> **NCT05308264** · PHASE1,PHASE2 · RECRUITING · sponsor: **Rigel Pharmaceuticals** · enrollment: 86 (estimated)

## Conditions studied

- Low Risk Myelodysplastic Syndromes

## Interventions

- **DRUG:** R906289 Monosodium (R289 Na)

## Key facts

- **NCT ID:** NCT05308264
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-12
- **Primary completion:** 2026-08
- **Final completion:** 2026-12
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05308264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05308264, "Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05308264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*